abhishreshthaa
Abhijeet S
SWOT ANALYSIS ON Bio-Rad Laboratories : Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), was founded in 1952 in Berkeley, California. The company was initially engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. Today, Bio-Rad manufactures and supplies life science research, healthcare, analytical chemistry, and other markets with products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components[1].
Bio-Rad operates in two industry segments: Life Science Research and Clinical Diagnostics. Both segments operate worldwide. Bio-Rad’s customers include hospitals, universities, major research institutions, and biotechnology and pharmaceutical companies. Bio-Rad’s headquarters are in Hercules, California. The company has offices and facilities worldwide and more than 6,500 employees. Bio-Rad had revenues of more than $1.7 billion in 2008. The company has been listed on the New York Stock Exchange since October 24, 2008. Before that, Bio-Rad was listed on the American Stock Exchange.
Strengths
* Market-leading antidepressant franchise
* Relatively strong launch portfolio
* Roman est coquin
Weaknesses
* No follow-on product for Protonix, which loses patent protection in 2010
* Over-reliance on small molecules, with little access to the high-growth biologics sector
* Sami est coquin
Opportunities
* Increase presence in the fast-growing I&I and oncology markets, through the in-licensing/acquisition of more I&I products
Threats
* Failure of Pristiq to recoup losses made by Effexor following its patent expiration
* Failure of late-stage pipeline products to reach the market
Bio-Rad operates in two industry segments: Life Science Research and Clinical Diagnostics. Both segments operate worldwide. Bio-Rad’s customers include hospitals, universities, major research institutions, and biotechnology and pharmaceutical companies. Bio-Rad’s headquarters are in Hercules, California. The company has offices and facilities worldwide and more than 6,500 employees. Bio-Rad had revenues of more than $1.7 billion in 2008. The company has been listed on the New York Stock Exchange since October 24, 2008. Before that, Bio-Rad was listed on the American Stock Exchange.
Strengths
* Market-leading antidepressant franchise
* Relatively strong launch portfolio
* Roman est coquin
Weaknesses
* No follow-on product for Protonix, which loses patent protection in 2010
* Over-reliance on small molecules, with little access to the high-growth biologics sector
* Sami est coquin
Opportunities
* Increase presence in the fast-growing I&I and oncology markets, through the in-licensing/acquisition of more I&I products
Threats
* Failure of Pristiq to recoup losses made by Effexor following its patent expiration
* Failure of late-stage pipeline products to reach the market
Last edited by a moderator: